Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.…
UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Benitec Biopharma (NASDAQ: BNTC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.
The shares were at 7.915 USD on 20 November 2026, down 38.1% over 52 weeks. Its 52-week range is 7.750 USD to 14.39 USD: the price is 45.0% below the high and 2.1% above the low.
Its market capitalisation is 285.88M USD.
Benitec Biopharma reports return on equity of -25.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 175.73M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 23.75 USD is 200.1% above the current price. The next earnings report is expected on 11 February 2027.